Homepage
Author:
Ernexa Therapeutics Inc.
Posted Date:
May 6, 2026
Ernexa Therapeutics Unveils Breakthrough Preclinical Results: ERNA-101 Achieves 100% Survival and Complete Tumor Elimination in Ovarian Cancer Models
Ernexa Therapeutics Inc.
May 6, 2026
Ernexa Therapeutics Announces 1-for-25 Reverse Stock Split
Ernexa Therapeutics Inc.
April 30, 2026
Ernexa Therapeutics Highlights Key Catalysts as Company Advances Toward First-in-Human Clinical Trials in 2026
Ernexa Therapeutics Inc.
March 31, 2026
Ernexa Therapeutics to Participate in Virtual Investor Closing Bell Series
Ernexa Therapeutics Inc.
February 20, 2026
Ernexa Therapeutics Announces Pricing of $10.5 Million Public Offering
Ernexa Therapeutics Inc.
February 8, 2026
Ernexa Therapeutics Participates in Virtual Investor “What This Means” Segment Highlighting Recent Successful Pre-IND Meeting with U.S. FDA
Ernexa Therapeutics Inc.
February 3, 2026
Ernexa Therapeutics Selected as One of Only Ten Global Companies for Prestigious JETRO Japan Entry Acceleration Program
Ernexa Therapeutics Inc.
January 28, 2026
